Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JNJ-49095397 (RV568), an inhaled narrow-spectrum kinase inhibitor (NSKI), targets the α and γ isoforms of p38 MAPK and the SRC kinase family, particularly haematopoietic kinase (HCK). Demonstrating potent anti-inflammatory properties, it holds potential for research in chronic obstructive pulmonary disease (COPD) and asthma.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 88.00 | |
5 mg | In stock | $ 213.00 | |
10 mg | In stock | $ 347.00 | |
25 mg | In stock | $ 695.00 | |
50 mg | 6-8 weeks | $ 1,090.00 |
Description | JNJ-49095397 (RV568), an inhaled narrow-spectrum kinase inhibitor (NSKI), targets the α and γ isoforms of p38 MAPK and the SRC kinase family, particularly haematopoietic kinase (HCK). Demonstrating potent anti-inflammatory properties, it holds potential for research in chronic obstructive pulmonary disease (COPD) and asthma. |
Synonyms | RV568 |
Molecular Weight | 592.69 |
Formula | C34H36N6O4 |
CAS No. | 1220626-82-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
JNJ-49095397 1220626-82-3 RV 568 JNJ49095397 RV-568 RV568 JNJ 49095397 inhibitor inhibit